246 related articles for article (PubMed ID: 31251998)
41. Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.
Calvello R; Cianciulli A; Nicolardi G; De Nuccio F; Giannotti L; Salvatore R; Porro C; Trotta T; Panaro MA; Lofrumento DD
J Neuroimmune Pharmacol; 2017 Jun; 12(2):327-339. PubMed ID: 27987058
[TBL] [Abstract][Full Text] [Related]
42. Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson's disease.
Li Q; Shen C; Liu Z; Ma Y; Wang J; Dong H; Zhang X; Wang Z; Yu M; Ci L; Sun R; Shen R; Fei J; Huang F
Cell Prolif; 2021 Aug; 54(8):e13094. PubMed ID: 34312932
[TBL] [Abstract][Full Text] [Related]
43. Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson's disease therapy.
Zaitone SA; Ahmed E; Elsherbiny NM; Mehanna ET; El-Kherbetawy MK; ElSayed MH; Alshareef DM; Moustafa YM
Pharmacol Rep; 2019 Feb; 71(1):32-41. PubMed ID: 30368226
[TBL] [Abstract][Full Text] [Related]
44. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
45. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R
Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549
[TBL] [Abstract][Full Text] [Related]
46. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.
Minelli A; Conte C; Cacciatore I; Cornacchia C; Pinnen F
Amino Acids; 2012 Sep; 43(3):1359-67. PubMed ID: 22218995
[TBL] [Abstract][Full Text] [Related]
47. The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice.
Stuckenholz V; Bacher M; Balzer-Geldsetzer M; Alvarez-Fischer D; Oertel WH; Dodel RC; Noelker C
J Parkinsons Dis; 2013; 3(2):161-72. PubMed ID: 23938346
[TBL] [Abstract][Full Text] [Related]
48. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
Li Y; Liu W; Li L; Hölscher C
Neuropharmacology; 2016 Feb; 101():255-63. PubMed ID: 26453962
[TBL] [Abstract][Full Text] [Related]
49. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model.
Kang JM; Park HJ; Choi YG; Choe IH; Park JH; Kim YS; Lim S
Brain Res; 2007 Feb; 1131(1):211-9. PubMed ID: 17173870
[TBL] [Abstract][Full Text] [Related]
50. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
[TBL] [Abstract][Full Text] [Related]
51. Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Khasnavis S; Pahan K
J Neuroimmune Pharmacol; 2014 Sep; 9(4):569-81. PubMed ID: 24946862
[TBL] [Abstract][Full Text] [Related]
52. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
53. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
54. Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Ojha RP; Rastogi M; Devi BP; Agrawal A; Dubey GP
J Neuroimmune Pharmacol; 2012 Sep; 7(3):609-18. PubMed ID: 22527634
[TBL] [Abstract][Full Text] [Related]
55. Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol.
Khan MM; Kempuraj D; Thangavel R; Zaheer A
Neurochem Int; 2013 Mar; 62(4):379-88. PubMed ID: 23391521
[TBL] [Abstract][Full Text] [Related]
56. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats.
O'Neill E; Chiara Goisis R; Haverty R; Harkin A
J Neurosci Res; 2019 Jul; 97(7):804-816. PubMed ID: 30924171
[TBL] [Abstract][Full Text] [Related]
57. Neuroprotective effect of Valeriana wallichii rhizome extract against the neurotoxin MPTP in C57BL/6 mice.
Sridharan S; Mohankumar K; Jeepipalli SP; Sankaramourthy D; Ronsard L; Subramanian K; Thamilarasan M; Raja K; Chandra VK; Sadras SR
Neurotoxicology; 2015 Dec; 51():172-83. PubMed ID: 26522450
[TBL] [Abstract][Full Text] [Related]
58. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
59. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
Kim JI; Yang EJ; Lee MS; Kim YS; Huh Y; Cho IH; Kang S; Koh HK
Int J Neurosci; 2011 Apr; 121(4):209-17. PubMed ID: 21265705
[TBL] [Abstract][Full Text] [Related]
60. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Sharma N; Nehru B
Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
